| Antimicrobial peptides of the vaginal innate immunity and their role in the fight against sexually transmitted diseases H Madanchi, M Shoushtari, HH Kashani, S Sardari New microbes and new infections 34, 100627, 2020 | 40 | 2020 |
| Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses M Shoushtari, F Roohvand, M Salehi-Vaziri, A Arashkia, H Bakhshi, ... Human Vaccines & Immunotherapeutics 18 (5), 2079323, 2022 | 6 | 2022 |
| Taguchi array optimization of the reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for sensitive and rapid detection of dengue virus serotype 2 M Shoushtari, M Salehi-Vaziri, F Roohvand, A Arashkia, T Jalali, ... Biotechnology Letters 43, 2149-2160, 2021 | 6 | 2021 |
| Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years F Gholami, R Hamidi Farahani, A Karimi Rahjerdi, M Ahi, A Sheidaei, ... BMC Infectious Diseases 23 (1), 118, 2023 | 4 | 2023 |
| Designing vaccine candidates against dengue virus by in silico studies on structural and nonstructural domains M Shoushtari, L Mafakher, S Rahmati, M Salehi-Vaziri, A Arashkia, ... Molecular and Cellular Probes 63, 101818, 2022 | 4 | 2022 |
| Production of egg yolk antibody (IgY) against Vibrio cholerae O1: protective effect in mice M Shoushtari, AB Shooshtari, S Asadi, Y Karami, M Honari, GA Alizadeh, ... Avicenna Journal of Medical Biotechnology 15 (4), 239, 2023 | 1 | 2023 |
| Structure-based evaluation of the envelope domain III–nonstructural protein 1 (EDIII-NS1) fusion as a dengue virus vaccine candidate M Shoushtari, E Rismani, M Salehi-Vaziri, K Azadmanesh Journal of Biomolecular Structure and Dynamics, 1-19, 2024 | | 2024 |
| One-step and Rapid Identification of SARS-CoV-2 using Real-Time Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) M Shoushtari, M Zeinoddini, J Fathi, HK Alikhani, F Shiekhi Avicenna Journal of Medical Biotechnology 16 (1), 3, 2024 | | 2024 |
| Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial A Ansarifar, RH Farahani, AK Rahjerdi, M Ahi, A Sheidaei, K Gohari, ... Vaccine: X 15, 100401, 2023 | | 2023 |
| Detection of Shiga-like Toxin Produced by E. coli O157: H7 based on the LSPR Property of Gold Nanoparticles F Yaghoubi, M Zeinoddini, M Shoushtari Journal of Applied Biotechnology Reports 10 (3), 1091-1097, 2023 | | 2023 |
| Emergence of Mosquito-borne Viruses in Iran and Adjacent Countries: The Case of Chikungunya H Bakhshi, AM Jafari-Nozad, K Arzamani, H Ghasemzadeh-Moghaddam, ... Journal of Health Sciences & Surveillance System 11 (3), 397-407, 2023 | | 2023 |
